Last reviewed · How we verify

Product CM9241GRU

Ache Laboratorios Farmaceuticos S.A. · Phase 3 active Small molecule

Product CM9241GRU is a ACE inhibitor Small molecule drug developed by Ache Laboratorios Farmaceuticos S.A.. It is currently in Phase 3 development for Hypertension.

CM9241GRU is a drug that targets the renin-angiotensin system.

CM9241GRU is a drug that targets the renin-angiotensin system. Used for Hypertension.

At a glance

Generic nameProduct CM9241GRU
SponsorAche Laboratorios Farmaceuticos S.A.
Drug classACE inhibitor
TargetACE
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

CM9241GRU works by inhibiting the angiotensin-converting enzyme (ACE), which plays a key role in the renin-angiotensin system. This leads to a decrease in blood pressure and a reduction in the workload on the heart.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Product CM9241GRU

What is Product CM9241GRU?

Product CM9241GRU is a ACE inhibitor drug developed by Ache Laboratorios Farmaceuticos S.A., indicated for Hypertension.

How does Product CM9241GRU work?

CM9241GRU is a drug that targets the renin-angiotensin system.

What is Product CM9241GRU used for?

Product CM9241GRU is indicated for Hypertension.

Who makes Product CM9241GRU?

Product CM9241GRU is developed by Ache Laboratorios Farmaceuticos S.A. (see full Ache Laboratorios Farmaceuticos S.A. pipeline at /company/ache-laboratorios-farmaceuticos-s-a).

What drug class is Product CM9241GRU in?

Product CM9241GRU belongs to the ACE inhibitor class. See all ACE inhibitor drugs at /class/ace-inhibitor.

What development phase is Product CM9241GRU in?

Product CM9241GRU is in Phase 3.

What are the side effects of Product CM9241GRU?

Common side effects of Product CM9241GRU include Cough, Dizziness, Headache.

What does Product CM9241GRU target?

Product CM9241GRU targets ACE and is a ACE inhibitor.

Related